JENNIFER FOSTER to Neoplasm Recurrence, Local
This is a "connection" page, showing publications JENNIFER FOSTER has written about Neoplasm Recurrence, Local.
Connection Strength
1.289
-
Clinical Course and Impact of Breaks in Therapy for Children With Relapsed/Refractory Solid Tumors. Pediatr Blood Cancer. 2026 May; 73(5):e70199.
Score: 0.593
-
Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective Study. Pediatr Blood Cancer. 2026 May; 73(5):e70195.
Score: 0.148
-
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma. Cancer. 2025 Feb 15; 131(4):e35751.
Score: 0.138
-
Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615). Eur J Cancer. 2024 Sep; 209:114241.
Score: 0.133
-
Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). Clin Cancer Res. 2021 07 01; 27(13):3543-3548.
Score: 0.104
-
Efficacy of proton therapy in children with high-risk and locally recurrent neuroblastoma. Pediatr Blood Cancer. 2019 08; 66(8):e27786.
Score: 0.092
-
Dinutuximab for the treatment of pediatric patients with neuroblastoma. Drugs Today (Barc). 2017 Sep; 53(9):469-476.
Score: 0.082